Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas

Annals of Surgical Oncology

Volumn 17, Issue 7, 2010, Pages 1767-1776

  Kim, Jin C ^a   Choi, Jin S ^a   Roh, Seon A ^a   Cho, Dong H ^a   Kim, Tae W ^a   Kim, Yong S ^a,b  

^a Asan Medical Center   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; DEATH ASSOCIATED PROTEIN KINASE; FLUOROPYRIMIDINE; PROTEIN CACNA 1 G; PROTEIN MINT 1; PROTEIN MINT 2; PROTEIN MINT 31; PROTEIN MLH 1; UNCLASSIFIED DRUG; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; COLORECTAL CARCINOMA; CONTROLLED STUDY; CPG ISLAND; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; MICROSATELLITE INSTABILITY; PHENOTYPE; ADENOCARCINOMA; COLORECTAL TUMOR; DISEASE COURSE; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; COLORECTAL NEOPLASMS; CPG ISLANDS; DISEASE PROGRESSION; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954954112     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0901-y     Document Type: Article

References (41)

1. Jones P, Laird P. Cancer epigenetics comes of age. Nat Genet. 1999;21:163-7.
2. Zitt M, Zitt M, Müller HM. DNA methylation in colorectal cancer-impact on screening and therapy monitoring modalities? Dis Markers. 2007;23:51-71.
3. Chan AO, Broaddus RR, Houlihan PS, Issa JP, Hamilton SR, Rashid A. CpG island methylation in aberrant crypt foci of the colorectum. Am J Pathol. 2002;160:1823-30.
4. Iacopetta B, Grieu F, Li W, Ruszkiewicz A, Caruso M, Moore J, et al. APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer. Int J Cancer. 2006;119:2272-8.
5. Sweeney C, Boucher KM, Samowitz WS, Wolff RK, Albertsen H, Curtin K, et al. Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. Genes Chromosomes Cancer. 2009;48:1-9.
6. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135:1079-99.
7. Yamashita K, Dai T, Dai Y, Yamamoto F, Perucho M. Genetics supersedes epigenetics in colon cancer phenotype. Cancer Cell. 2003;4:121-31.
8. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007;132:127-38.
9. Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One. 2008;3: e3698.
10. Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch. 2007;450:529-37.
11. Nagasaka T, Sasamoto H, Notohara K, Cullings HM, Takeda M, Kimura K, et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol. 2004;22:4584-94.
12. Maier S, Dahlstroem C, Haefliger C, Plum A, Piepenbrock C. Identifying DNA methylation biomarkers of cancer drug response. Am J Pharmacogenomics. 2005;5:223-32.
13. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer. 2003;106:66-73.
14. Iacopetta B, Kawakami K, Watanabe T. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluor-ouracil-responsive subgroup? Int J Clin Oncol. 2008;13:498-503.
15. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc. 2007;2:2265-75.
16. Nosho K, Kure S, Irahara N, Shima K, Baba Y, Spiegelman D, et al. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology. 2009;137:1609-20.
17. Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa JP. Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res. 2000;60:4044-8.
18. Mittag F, Kuester D, Vieth M, Peters B, Stolte B, Roessner A, Schneider-Stock R. DAPK promotor methylation is an early event in colorectal carcinogenesis. Cancer Lett. 2006;240:69-75.
19. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38:787-93.
20. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58:90-6.
21. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008;68:8541-6.
22. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet. 1999;36:801-18.
23. Suehiro Y, Wong CW, Chirieac LR, Kondo Y, Shen L, Webb CR, et al. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma. Clin Cancer Res. 2008;14:2560-9.
24. Lind GE, Thorstensen L, Løvig T, Meling GI, Hamelin R, Rognum TO, et al. A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer. 2004;3:28.
25. Judson H, Stewart A, Leslie A, Pratt NR, Baty DU, Steele RJ, et al. Relationship between point gene mutation, chromosomal abnormality, and tumour suppressor gene methylation status in colorectal adenomas. J Pathol. 2006;210:344-50.
26. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn. 2006;8:582-8.
27. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA. 2007;104:18654-9.
28. Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Grieu F, Watanabe G, et al. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer. 2006;94:593-8. (Pubitemid 43289765)
29. INK4a gene promoter hypermethylation in mucosa as a prognostic factor for patients with colorectal cancer. Mol Med. 2008;14:412-21.
30. Issa JP. Aging, DNA methylation and cancer. Crit Rev Oncol Hematol. 1999;32:31-43.
31. Chirieac LR, Shen L, Catalano PJ, Issa JP, Hamilton SR. Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. Am J Surg Pathol. 2005;29:429-36.
32. Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100:266-73.
33. Alhaja E, Adan J, Pagan R, Mitjans F, Cascallo M, Rodriguez M, et al. Anti-migratory and anti-angiogenic effect of p16: a novel localization at membrane ruffles and lamellipodia in endothelial cells. Angiogenesis. 2004;7:323-33.
34. Trzeciak L, Hennig E, Kolodziejski J, Nowacki M, Ostrowski J. Mutations, methylation and expression of CDKN2a/p16 gene in colorectal cancer and normal colonic mucosa. Cancer Lett. 2001;163:17-23.
35. Nakayama G, Hibi K, Kodera Y, Koike M, Fujiwara M, Nakao A. p16 methylation in serum as a potential marker for the malignancy of colorectal carcinoma. Anticancer Res. 2007;27:3367-70. (Pubitemid 47607563)
36. Wang CH, Chang HC, Hung WC. p16 inhibits matrix metalloproteinase-2 expression via suppression of Sp1-mediated gene transcription. J Cell Physiol. 2006;208:246-52.
37. Morita S, Iida S, Kato K, Takagi Y, Uetake H, Sugihara K. The synergistic effect of 5-aza-20-deoxycytidine and 5-fluorouracil on drug-resistant tumors. Oncology. 2006;71:437-45.
38. Nagasaka T, Sharp GB, Notohara K, Kambara T, Sasamoto H, Isozaki H, et al. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases. Clin Cancer Res. 2003;9:5306-12.
39. Skorpen F, Krokan HE. The methylation status of the gene for O6-methylguanine-DNA methyltransferase in human Mer+ and Mercells. Carcinogenesis. 1995;16:1857-63.
40. Hawkins NJ, Lee JH, Wong JJ, Kwok CT, Ward RL, Hitchins MP. MGMT methylation is associated primarily with the germ-line C[T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol. 2009;22:1588-99.
41. Ogino S, Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut. 2007;56:1564-71.